Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

Next Previous
X
Search
Trial Profile

A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plazomicin (Primary) ; Antibacterials; Colistin; Meropenem; Tigecycline
  • Indications Bacteraemia; Enterobacteriaceae infections; Gram-negative infections; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms CARE
  • Sponsors Achaogen

    • Most Recent Events

    • 28 Mar 2019 According to an Achaogen media release, the Company has received the Day 120 List of Questions from the European Medicines Agency (EMA) as part of the centralized review process of the MAA for plazomicin.
    • 21 Feb 2019 According to an Achaogen media release, full study results of this trial are published in the New England Journal of Medicine (Letter to the Editor and Supplementary Appendix, 21st Feb 2019, issue of the Journal).
    • 14 Feb 2019 According to an Achaogen media release, in response to the MAA application filed in the fourth quarter of 2018, the Company anticipates receiving the Day 120 questions by the end of the first quarter of 2019, after which it will continue to advance the regulatory process with the rapporteurs and the EMA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top